GlassScriptPhysician profile
Jessica A Balvitsch
NPI 1043316524
$909.47
in general payments reported to CMS, 2019-2025
16 companies · $236 in 2025
The $236 reported for 2025 was less than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $207 · 2023: $210 · 2024: $256 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $702.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $702.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $121.83 | 2022-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $119.32 | 2022-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $98.83 | 2022-2025 | Caplyta |
| Lundbeck LLC | $76.21 | 2022-2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $75.71 | 2024-2025 | Uzedy |
| Otsuka America Pharmaceutical, INC. | $66.69 | 2022-2025 | Rexulti |
| Sage Therapeutics, LLC | $60.46 | 2024-2025 | Zurzuvae |
| Acadia Pharmaceuticals INC | $52.92 | 2022-2025 | Nuplazid |
| Vanda Pharmaceuticals INC. | $46.01 | 2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $36.64 | 2023 | Trintellix |
| Abbvie INC. | $34.69 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $29.50 | 2023 | Belsomra |
| Janssen Pharmaceuticals, INC | $27.13 | 2023 | Spravato, Invega Sustenna, Invega Trinza |
| Grt US Holding, INC. | $23.96 | 2022 | |
| Axsome Therapeutics, INC. | $19.99 | 2024 | Auvelity |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $19.58 | 2024 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Balvitsch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.